Do analysts rate EVAX or CELZ?

Evaxion A/S presently has a consensus target price of $11.00, suggesting a potential upside of 203.87%. Given Evaxion A/S's stronger consensus rating and higher possible upside, equities analysts clearly believe Evaxion A/S is more favorable than Creative Medical Technology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evaxion A/S 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67 Creative Medical Technology 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is EVAX or CELZ more profitable?

Evaxion A/S's return on equity of -73.56% beat Creative Medical Technology's return on equity. Company Net Margins Return on Equity Return on Assets Evaxion A/S N/A -73.56% -37.45% Creative Medical Technology N/A -88.38% -84.71%

Do analysts prefer CELZ or VIRI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Creative Medical Technology 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Virios Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is CELZ or VIRI more profitable?

Creative Medical Technology's return on equity of -88.38% beat Virios Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Creative Medical Technology N/A -88.38% -84.71% Virios Therapeutics N/A -130.33% -115.00%

Do analysts recommend DARE or CELZ?

Dare Bioscience presently has a consensus price target of $10.00, suggesting a potential upside of 382.86%. Given Dare Bioscience's stronger consensus rating and higher possible upside, research analysts plainly believe Dare Bioscience is more favorable than Creative Medical Technology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dare Bioscience 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Creative Medical Technology 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is DARE or CELZ more profitable?

Dare Bioscience's return on equity of 0.00% beat Creative Medical Technology's return on equity. Company Net Margins Return on Equity Return on Assets Dare Bioscience N/A N/A -46.22% Creative Medical Technology N/A -88.38% -84.71%

Do analysts prefer LITS or CELZ?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lite Strategy 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Creative Medical Technology 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is LITS or CELZ more profitable?

Creative Medical Technology's return on equity of -88.38% beat Lite Strategy's return on equity. Company Net Margins Return on Equity Return on Assets Lite Strategy N/A -90.81% -89.33% Creative Medical Technology N/A -88.38% -84.71%

Creative Medical Technology (CELZ) Competitors

$2.17 -0.06 (-2.47%)

As of 02:00 PM Eastern

Compare

CELZ vs. EVAX, ALGS, VIRI, DARE, and LITS

Should you buy Creative Medical Technology stock or one of its competitors? MarketBeat compares Creative Medical Technology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Creative Medical Technology include Evaxion A/S (EVAX), Aligos Therapeutics (ALGS), Virios Therapeutics (VIRI), Dare Bioscience (DARE), and Lite Strategy (LITS). These companies are all part of the "pharmaceutical products" industry.

How does Creative Medical Technology compare to Evaxion A/S?

Evaxion A/S (NASDAQ:EVAX) and Creative Medical Technology (NASDAQ:CELZ) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends, analyst recommendations and media sentiment.

11.0% of Evaxion A/S shares are held by institutional investors. Comparatively, 1.4% of Creative Medical Technology shares are held by institutional investors. 41.6% of Evaxion A/S shares are held by insiders. Comparatively, 1.7% of Creative Medical Technology shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Evaxion A/S has a beta of 0.24, meaning that its stock price is 76% less volatile than the broader market. Comparatively, Creative Medical Technology has a beta of 1.84, meaning that its stock price is 84% more volatile than the broader market.

Evaxion A/S presently has a consensus target price of $11.00, suggesting a potential upside of 203.87%. Given Evaxion A/S's stronger consensus rating and higher possible upside, equities analysts clearly believe Evaxion A/S is more favorable than Creative Medical Technology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evaxion A/S	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Creative Medical Technology	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Evaxion A/S's return on equity of -73.56% beat Creative Medical Technology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evaxion A/S	N/A	-73.56%	-37.45%
Creative Medical Technology	N/A	-88.38%	-84.71%

In the previous week, Evaxion A/S and Evaxion A/S both had 1 articles in the media. Creative Medical Technology's average media sentiment score of 1.90 beat Evaxion A/S's score of 1.87 indicating that Creative Medical Technology is being referred to more favorably in the news media.

Company	Overall Sentiment
Evaxion A/S	Very Positive
Creative Medical Technology	Very Positive

Creative Medical Technology has lower revenue, but higher earnings than Evaxion A/S. Evaxion A/S is trading at a lower price-to-earnings ratio than Creative Medical Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evaxion A/S	$7.53M	4.01	-$7.71M	-$1.47	N/A
Creative Medical Technology	$10K	804.75	-$5.99M	-$2.14	N/A

Summary

Evaxion A/S beats Creative Medical Technology on 9 of the 14 factors compared between the two stocks.

How does Creative Medical Technology compare to Aligos Therapeutics?

Aligos Therapeutics (NASDAQ:ALGS) and Creative Medical Technology (NASDAQ:CELZ) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, risk, valuation, institutional ownership and analyst recommendations.

Creative Medical Technology has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -1,919.68%. Creative Medical Technology's return on equity of -88.38% beat Aligos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aligos Therapeutics	-1,919.68%	-139.47%	-90.88%
Creative Medical Technology	N/A	-88.38%	-84.71%

In the previous week, Aligos Therapeutics had 1 more articles in the media than Creative Medical Technology. MarketBeat recorded 2 mentions for Aligos Therapeutics and 1 mentions for Creative Medical Technology. Creative Medical Technology's average media sentiment score of 1.90 beat Aligos Therapeutics' score of 1.22 indicating that Creative Medical Technology is being referred to more favorably in the news media.

Company	Overall Sentiment
Aligos Therapeutics	Positive
Creative Medical Technology	Very Positive

Aligos Therapeutics has a beta of 2.25, meaning that its share price is 125% more volatile than the broader market. Comparatively, Creative Medical Technology has a beta of 1.84, meaning that its share price is 84% more volatile than the broader market.

Aligos Therapeutics currently has a consensus price target of $38.50, suggesting a potential upside of 642.53%. Given Aligos Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Aligos Therapeutics is more favorable than Creative Medical Technology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aligos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Creative Medical Technology	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

60.4% of Aligos Therapeutics shares are held by institutional investors. Comparatively, 1.4% of Creative Medical Technology shares are held by institutional investors. 7.8% of Aligos Therapeutics shares are held by company insiders. Comparatively, 1.7% of Creative Medical Technology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Creative Medical Technology has lower revenue, but higher earnings than Aligos Therapeutics. Creative Medical Technology is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aligos Therapeutics	$2.19M	14.66	-$24.19M	-$8.69	N/A
Creative Medical Technology	$10K	804.75	-$5.99M	-$2.14	N/A

Summary

Aligos Therapeutics beats Creative Medical Technology on 10 of the 17 factors compared between the two stocks.

How does Creative Medical Technology compare to Virios Therapeutics?

Creative Medical Technology (NASDAQ:CELZ) and Virios Therapeutics (NASDAQ:VIRI) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation.

1.4% of Creative Medical Technology shares are owned by institutional investors. Comparatively, 9.1% of Virios Therapeutics shares are owned by institutional investors. 1.7% of Creative Medical Technology shares are owned by company insiders. Comparatively, 12.2% of Virios Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Creative Medical Technology	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Virios Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Creative Medical Technology's return on equity of -88.38% beat Virios Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Creative Medical Technology	N/A	-88.38%	-84.71%
Virios Therapeutics	N/A	-130.33%	-115.00%

In the previous week, Creative Medical Technology and Creative Medical Technology both had 1 articles in the media. Creative Medical Technology's average media sentiment score of 1.90 beat Virios Therapeutics' score of 0.75 indicating that Creative Medical Technology is being referred to more favorably in the media.

Company	Overall Sentiment
Creative Medical Technology	Very Positive
Virios Therapeutics	Positive

Creative Medical Technology has a beta of 1.84, suggesting that its share price is 84% more volatile than the broader market. Comparatively, Virios Therapeutics has a beta of 1.58, suggesting that its share price is 58% more volatile than the broader market.

Virios Therapeutics has lower revenue, but higher earnings than Creative Medical Technology. Virios Therapeutics is trading at a lower price-to-earnings ratio than Creative Medical Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Creative Medical Technology	$10K	804.75	-$5.99M	-$2.14	N/A
Virios Therapeutics	N/A	N/A	-$5.30M	-$0.27	N/A

Summary

Creative Medical Technology beats Virios Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Creative Medical Technology compare to Dare Bioscience?

Dare Bioscience (NASDAQ:DARE) and Creative Medical Technology (NASDAQ:CELZ) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, dividends, media sentiment, institutional ownership, analyst recommendations and profitability.

Dare Bioscience presently has a consensus price target of $10.00, suggesting a potential upside of 382.86%. Given Dare Bioscience's stronger consensus rating and higher possible upside, research analysts plainly believe Dare Bioscience is more favorable than Creative Medical Technology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dare Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Creative Medical Technology	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Creative Medical Technology has lower revenue, but higher earnings than Dare Bioscience. Dare Bioscience is trading at a lower price-to-earnings ratio than Creative Medical Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dare Bioscience	$1.03M	30.12	-$13.40M	-$0.95	N/A
Creative Medical Technology	$10K	804.75	-$5.99M	-$2.14	N/A

Dare Bioscience has a beta of 1.07, meaning that its stock price is 7% more volatile than the broader market. Comparatively, Creative Medical Technology has a beta of 1.84, meaning that its stock price is 84% more volatile than the broader market.

6.7% of Dare Bioscience shares are held by institutional investors. Comparatively, 1.4% of Creative Medical Technology shares are held by institutional investors. 4.1% of Dare Bioscience shares are held by insiders. Comparatively, 1.7% of Creative Medical Technology shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Dare Bioscience's return on equity of 0.00% beat Creative Medical Technology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dare Bioscience	N/A	N/A	-46.22%
Creative Medical Technology	N/A	-88.38%	-84.71%

In the previous week, Dare Bioscience had 1 more articles in the media than Creative Medical Technology. MarketBeat recorded 2 mentions for Dare Bioscience and 1 mentions for Creative Medical Technology. Creative Medical Technology's average media sentiment score of 1.90 beat Dare Bioscience's score of 0.73 indicating that Creative Medical Technology is being referred to more favorably in the news media.

Company	Overall Sentiment
Dare Bioscience	Positive
Creative Medical Technology	Very Positive

Summary

Dare Bioscience beats Creative Medical Technology on 10 of the 15 factors compared between the two stocks.

How does Creative Medical Technology compare to Lite Strategy?

Lite Strategy (NASDAQ:LITS) and Creative Medical Technology (NASDAQ:CELZ) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, media sentiment, valuation and risk.

Lite Strategy has a beta of 0.21, indicating that its share price is 79% less volatile than the broader market. Comparatively, Creative Medical Technology has a beta of 1.84, indicating that its share price is 84% more volatile than the broader market.

In the previous week, Lite Strategy and Lite Strategy both had 1 articles in the media. Creative Medical Technology's average media sentiment score of 1.90 beat Lite Strategy's score of 1.87 indicating that Creative Medical Technology is being referred to more favorably in the news media.

Company	Overall Sentiment
Lite Strategy	Very Positive
Creative Medical Technology	Very Positive

Creative Medical Technology's return on equity of -88.38% beat Lite Strategy's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lite Strategy	N/A	-90.81%	-89.33%
Creative Medical Technology	N/A	-88.38%	-84.71%

Creative Medical Technology has lower revenue, but higher earnings than Lite Strategy. Creative Medical Technology is trading at a lower price-to-earnings ratio than Lite Strategy, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lite Strategy	$65.30M	0.43	-$15.94M	-$1.60	N/A
Creative Medical Technology	$10K	804.75	-$5.99M	-$2.14	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lite Strategy	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Creative Medical Technology	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

52.4% of Lite Strategy shares are held by institutional investors. Comparatively, 1.4% of Creative Medical Technology shares are held by institutional investors. 1.6% of Lite Strategy shares are held by insiders. Comparatively, 1.7% of Creative Medical Technology shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Creative Medical Technology beats Lite Strategy on 8 of the 12 factors compared between the two stocks.

Get Creative Medical Technology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CELZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CELZ vs. The Competition

Export

Metric	Creative Medical Technology	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$8.05M	$3.27B	$6.26B	$12.43B
Dividend Yield	N/A	2.33%	2.69%	5.29%
P/E Ratio	-1.02	17.91	22.42	24.23
Price / Sales	804.75	322.86	548.01	125.38
Price / Cash	N/A	116.27	42.31	57.88
Price / Book	1.07	6.59	9.82	6.71
Net Income	-$5.99M	$24.20M	$3.56B	$337.09M
7 Day Performance	-5.84%	-3.13%	-1.17%	0.63%
1 Month Performance	-2.90%	0.44%	3.71%	5.15%
1 Year Performance	-5.02%	46.70%	27.28%	34.36%

Creative Medical Technology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CELZ Creative Medical Technology	1.1989 of 5 stars	$2.18 -2.5%	N/A	+1.8%	$8.05M	$10K	N/A	5	Positive News
EVAX Evaxion A/S	4.0136 of 5 stars	$4.15 +2.3%	$11.00 +165.4%	+37.9%	$34.57M	$7.53M	N/A	60	Positive News
ALGS Aligos Therapeutics	3.9012 of 5 stars	$5.55 -0.9%	$38.50 +593.7%	+0.0%	$34.37M	$2.19M	N/A	90	Positive News
VIRI Virios Therapeutics	N/A	$1.78 -0.6%	N/A	-67.2%	$34.28M	N/A	N/A	5
DARE Dare Bioscience	2.0185 of 5 stars	$2.26 -3.2%	$10.00 +343.5%	-29.4%	$33.78M	$1.03M	N/A	30	Short Interest Increase

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CELZ) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Creative Medical Technology (CELZ) Competitors

CELZ vs. EVAX, ALGS, VIRI, DARE, and LITS

How does Creative Medical Technology compare to Evaxion A/S?

Summary

How does Creative Medical Technology compare to Aligos Therapeutics?

Summary

How does Creative Medical Technology compare to Virios Therapeutics?

Summary

How does Creative Medical Technology compare to Dare Bioscience?

Summary

How does Creative Medical Technology compare to Lite Strategy?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CELZ vs. The Competition

Creative Medical Technology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Creative Medical Technology (CELZ) Competitors

CELZ vs. EVAX, ALGS, VIRI, DARE, and LITS

How does Creative Medical Technology compare to Evaxion A/S?

Do insiders and institutionals hold more shares of EVAX or CELZ?

Which has more risk and volatility, EVAX or CELZ?

Do analysts rate EVAX or CELZ?

Is EVAX or CELZ more profitable?

Does the media refer more to EVAX or CELZ?

Which has better earnings and valuation, EVAX or CELZ?

Summary

How does Creative Medical Technology compare to Aligos Therapeutics?

Is ALGS or CELZ more profitable?

Does the media refer more to ALGS or CELZ?

Which has more volatility and risk, ALGS or CELZ?

Do analysts recommend ALGS or CELZ?

Do insiders & institutionals hold more shares of ALGS or CELZ?

Which has higher valuation and earnings, ALGS or CELZ?

Summary

How does Creative Medical Technology compare to Virios Therapeutics?

Do institutionals and insiders believe in CELZ or VIRI?

Do analysts prefer CELZ or VIRI?

Is CELZ or VIRI more profitable?

Does the media prefer CELZ or VIRI?

Which has more risk and volatility, CELZ or VIRI?

Which has stronger earnings and valuation, CELZ or VIRI?

Summary

How does Creative Medical Technology compare to Dare Bioscience?

Do analysts recommend DARE or CELZ?

Which has stronger valuation & earnings, DARE or CELZ?

Which has more risk and volatility, DARE or CELZ?

Do institutionals & insiders hold more shares of DARE or CELZ?

Is DARE or CELZ more profitable?

Does the media refer more to DARE or CELZ?

Summary

How does Creative Medical Technology compare to Lite Strategy?

Which has more volatility & risk, LITS or CELZ?

Does the media refer more to LITS or CELZ?

Is LITS or CELZ more profitable?

Which has stronger valuation & earnings, LITS or CELZ?

Do analysts prefer LITS or CELZ?

Do insiders & institutionals have more ownership in LITS or CELZ?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CELZ vs. The Competition

Creative Medical Technology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools